Have any questions? 706-721-6582 or cts@augusta.edu
- SLSG18-301: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Clinical Trial
SLSG18-301: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Patients are being asked to take part in this study because they have Acute Myeloid Leukemia (AML). The main purpose of this study is to compare the effectiveness of the study drug, GPS with the study doctor's choice of best available therapy on the overall survival rate in patients with AML, who are in second complete remission or second complete remission with incomplete platelet recovery. The study also aims to determine how safe GPS is, and whether any of its side effects can be tolerated by patients.
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with diagnosed acute myeloid leukemia Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.